Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
Between January 2020 and June 2026, the FDA approved 28 peptide-based drugs and the EMA approved 22, representing approximately eight percent of all new molecular entity approvals over this period. The regulatory landscape for peptides has evolved significantly, with new guidance documents, a dedicated FDA peptide working group, and a growing body of precedent for novel modalities including macrocycles, peptide-drug conjugates, and multi-receptor agonists. This analysis maps the trends, the precedents, and what they mean for developers.
Approval Trends by Therapeutic Area
Rare Disease | 5 | Zilucoplan, glepaglutide, vosoritide | 10.4.
Infectious Disease | 4 | Rezafungin, ibrexafungerp, enfuvirtide follow-ons | 8.1.
Oncology approvals benefit from the fastest review times due to the prevalence of accelerated approval and breakthrough therapy designation — 6 of 7 oncology peptide approvals used one of these expedited pathways. Metabolic disease approvals, while slightly slower, benefit from the FDA’s growing familiarity with GLP-1 class molecules and the existence of well-validated surrogate endpoints (HbA1c, body weight). The rare disease category shows the widest variance in review times, with some approvals completed in 6 months (zilucoplan, priority review) and others requiring 18+ months following complete response letters.
The 2025 FDA Peptide Guidance: What Changed
In October 2025, the FDA issued ” peptide drug products” (draft guidance) — the agency’s first dedicated guidance for peptide therapeutics since the 1994 ” peptide drug products” document. The 2025 guidance contains three significant developments:
1. Macrocycles as a distinct category. The guidance explicitly acknowledges cyclic and macrocyclic peptides as a distinct therapeutic modality, with specific recommendations for characterizing conformational heterogeneity, demonstrating batch-to-batch cyclization consistency, and establishing acceptance criteria for cyclic vs. linear impurity profiles. This is a meaningful shift from the previous practice of evaluating macrocycles under small-molecule or biologic frameworks — neither of which adequately addressed their unique properties.
2. Peptide impurity thresholds. The guidance proposes that individual peptide-related impurities above 0.5 percent must be identified and characterized, with a reporting threshold of 0.1 percent. For comparison, small-molecule drugs typically have identification thresholds of 0.1–0.2 percent. The higher threshold for peptides reflects the inherent complexity of SPPS impurity profiles and the practical difficulty of identifying every deletion and epimerization product in a 30+ residue peptide.
3. Immunogenicity assessment. While peptides have lower inherent immunogenicity than biologics, the guidance recommends in silico T-cell epitope screening for all peptide therapeutics intended for chronic administration (more than 30 days). This recommendation brings peptide immunogenicity assessment closer to the standards applied to monoclonal antibodies and represents a new regulatory expectation for the field.
Expert Insight: The ANDA Pathway for Peptides
One of the most consequential regulatory developments for the peptide industry is the evolving ANDA pathway for peptide generics. Historically, most peptide drugs were approved under NDAs with no clear generic pathway — the FDA considered peptides too complex for traditional small-molecule generic approval. This began to change with the 2021 approval of the first peptide ANDA — glatiramer acetate generic —, and the 2025 guidance formalized criteria for when a peptide can be approved via ANDA: the peptide must befully characterized by physicochemical methods (mass spectrometry, NMR, amino acid analysis), must demonstrate sameness of active ingredient (same sequence, same disulfide bond pattern, same aggregation state), and must not rely on clinical data to establish safety or efficacy.
Practical implication: Peptides synthesized by SPPS with well-characterized impurity profiles are increasingly viable for ANDA approval. Peptides produced by recombinant methods or containing non-ribosomal modifications are unlikely to qualify for the ANDA pathway and will require 505 (b)(2) NDAs with at least some clinical data.
[Natural sign-off — one sentence summary of why this matters.]
Further Reading
- Peptide Therapeutics Market Report H1 2026
- The Peptide Patent Cliff — regulatory implications of patent expiry
Last reviewed: June 2026. Peptide Proof Editorial Team.
